1-5 of 5
Luqiang Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

David M. Kurtz, Gregory Hogan, Andre Schultz, Jacob J. Chabon, Ash A. Alizadeh, Karin Havenith, Sara Samari, Tim Kopotsha, Luqiang Wang, Yajuan Qin, Ying Wang, Serafino Pantano
Journal: Blood
Blood (2023) 142 (Supplement 1): 3133.
https://doi.org/10.1182/blood-2023-179977
Published: 2023
Journal Articles

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Alex F. Herrera, Stephen M. Ansell, Pier Luigi Zinzani, John Radford, Kami J. Maddocks, Antonio Pinto, Graham P. Collins, Veronika Bachanova, Nancy L. Bartlett, Isabelle Bence-Bruckler, Mehdi Hamadani, Justin Kline, Jiri Mayer, Kerry J. Savage, Ranjana H. Advani, Paolo F. Caimi, René-Olivier Casasnovas, Tatyana A. Feldman, Brian T. Hess, Mariana Bastos-Oreiro, Sunil Iyengar, Árpád Szomor, William Townsend, Marc Andre, Jerzy Dyczkowski, Sandy Eisen, Andrzej Urban, Serafino Pantano, Hans G. Cruz, Luqiang Wang, Yanina Negievich, Jens Wuerthner, Carmelo Carlo-Stella
Journal: Blood
Blood (2022) 140 (Supplement 1): 3673–3677.
https://doi.org/10.1182/blood-2022-157583
Published: 2022
Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Clinical Trials & Observations
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl
Journal: Blood
Blood (2021) 137 (19): 2634–2645.
https://doi.org/10.1182/blood.2020007512
Published: 2021
Includes: Supplemental data
Journal Articles

Symptoms, Health-Related Quality of Life, and Tolerability of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Alexander I. Spira, PhD MD FACP, Lei Chen, MD PhD, Xiaolei Zhou, Ari Gnanasakthy, Luqiang Wang, David Ungar, Rafael Curiel, John A. Radford, MD FMedSci, Brad S. Kahl, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-139571
Published: 2020
Journal Articles

Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Alex F. Herrera, MD, Carmelo Carlo-Stella, MD, Graham P. Collins, MD DPhil, Kami J. Maddocks, MD, Nancy L. Bartlett, MD, Kerry J. Savage, MDMSc, Paolo F Caimi, Brian T. Hess, MD, Pier Luigi Zinzani, MD, Hans G Cruz, Luqiang Wang, Jay Feingold, Jens Wuerthner, Stephen M. Ansell, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–23.
https://doi.org/10.1182/blood-2020-137451
Published: 2020